Implantable cardioverter defibrillator with and without defibrillation threshold testing.

Area of Science:

• Cardiology
• Medical Devices
• Clinical Trials

Background:

• Routine defibrillation threshold (DFT) testing during implantable cardioverter defibrillator (ICD) insertion is standard practice.
• Concerns exist regarding DFT's efficacy in improving ICD function and its impact on patient survival.

Purpose of the Study:

• To compare outcomes between ICD recipients who underwent DFT testing and those who did not.
• Evaluate the effect of DFT testing on mortality, ICD shocks, and anti-tachycardia pacing (ATP).

Main Methods:

• A cohort of 213 patients receiving ICDs between 2004-2009 was analyzed.
• 80 patients underwent DFT testing; outcomes were compared over a 2-year follow-up.
• Key metrics included total mortality, ICD shocks (appropriate/inappropriate), and ATP events.

Main Results:

• Two-year mortality rates were similar: 7.5% (DFT group) vs. 8.3% (non-DFT group) (P=0.8).
• ICD shock incidence was 20.7% (DFT) vs. 12.4% (non-DFT) (P=0.15).
• Appropriate ICD treatment rates (shocks or ATP) were 57.7% (DFT) vs. 64.2% (non-DFT) (P=0.78).

Conclusions:

• No significant differences were observed in 2-year mortality between DFT and non-DFT groups.
• The incidence of ICD treatment did not significantly differ between the two groups.
• Findings question the routine necessity of DFT testing for ICD recipients.